Abstract
MicroRNA-155 (miR-155) is a small noncoding RNA critical for the regulation of inflammation as well as innate and adaptive immune responses. MiR-155 has been shown to be dysregulated in both donor and recipient immune cells during acute graftversushost disease (aGVHD). We previously reported that miR-155 is upregulated in donor T cells of mice and humans with aGVHD and that mice receiving miR-155-deficient (miR155 -/- ) splenocytes had markedly reduced aGVHD. However, molecular mechanisms by which miR-155 modulates T cell function in aGVHD have not been fully investigated. We identify that miR-155 expression in both donor CD8+ T cells and conventional CD4 + CD25 - T cells is pivotal for aGVHD pathogenesis. Using murine aGVHD transplant experiments, we show that miR-155 strongly impacts alloreactive T cell expansion through multiple distinct mechanisms, modulating proliferation in CD8+ donor T cells and promoting exhaustion in donor CD4+ T cells in both the spleen and colon. Additionally, miR-155 drives a proinflammatory Th1 phenotype in donor T cells in these two sites, and miR-1552/2 donor T cells are polarized toward an IL-4-producing Th2 phenotype. We further demonstrate that miR-155 expression in donor T cells regulates CCR5 and CXCR4 chemokine-dependent migration. Notably, we show that miR-155 expression is crucial for donor T cell infiltration into multiple target organs. These findings provide further understanding of the role of miR-155 in modulating aGVHD through T cell expansion, effector cytokine production, and migration.
Original language | English (US) |
---|---|
Pages (from-to) | 4170-4179 |
Number of pages | 10 |
Journal | Journal of Immunology |
Volume | 200 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2018 |
Bibliographical note
Funding Information:This work was supported by National Institutes of Health Grants 1R21HL117707-01R01 (to Y.A.E. and R.G.), T32 5T32CA009338-37 (to N.C.Z.), HL56067, AI344965, and HL11879 (to B.R.B.), a Leukemia and Lymphoma Society Special Fellow Award (to P.R.), a Leukemia and Lymphoma Society Scholar Award (to R.G.), and an American Cancer Society Research Scholar Award (to R.G.).